Nitroxoline induces apoptosis and slows glioma growth in vivo

Neuro-Oncology

Volumn 17, Issue 1, 2015, Pages 53-62

  Lazovic, Jelena ^a   Guo, Lea ^a   Nakashima, Jonathan ^b   Mirsadraei, Leili ^c   Yong, William ^b   Kim, Hyun J ^a,b   Ellingson, Benjamin ^a   Wu, Hong ^b   Pope, Whitney B ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

8 hydroxy 5 nitroquinoline; Glioma animal model; Invasion; Nitroxoline; PTEN

Indexed keywords

CASPASE 3; DIGOXIGENIN; K RAS PROTEIN; NITROXOLINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); VASCULOTROPIN; ANTINEOPLASTIC AGENT; NITROQUINOLINE DERIVATIVE; URINARY TRACT ANTIINFECTIVE AGENT;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BRAIN HISTOLOGY; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG APPROVAL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC ENGINEERING; GLIOMA; GLIOMA CELL; GLIOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NICK END LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR INVASION; U251 CELL; U87 CELL; URINARY TRACT INFECTION; ANIMAL; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINT; DISEASE MODEL; DRUG EFFECTS; GLIOBLASTOMA; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTI-INFECTIVE AGENTS, URINARY; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; MICE; NITROQUINOLINES;

EID: 84922487645     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou139     Document Type: Article

References (31)

1. Johnson DR, ONeill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107(2):359-364.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Jiang H, Taggart JE, Zhang X, et al. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett. 2011; 312(1):11-17.
4. Shim JS, Matsui Y, Bhat S, et al. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst. 2011;102(24):1855-1873.
5. Sosic I, Mirkovic B, Arenz K, et al. Development of new cathepsin B inhibitors: combining bioisosteric replacements and structurebased design to explore the structure-activity relationships of nitroxoline derivatives. J Med Chem. 2013;56(2):521-533.
6. Mirkovic B, Renko M, Turk S, et al. Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and related compounds. ChemMedChem. 2011;6(8):1351-1356.
7. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep. 1998;5(6):1349-1361.
8. Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta. 2004;342(1-2):41-69.
9. Mai J, Sameni M, Mikkelsen T, et al. Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas. Biol Chem. 2002;383(9): 1407-1413.
10. Sobke A, Klinger M, Hermann B, et al. The urinary antibiotic 5-nitro-8-hydroxyquinoline (Nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc. Antimicrob Agents Chemother. 2012;56(11):6021-6025.
11. de Vries NA, Bruggeman SW, Hulsman D, et al. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. Clin Cancer Res. 2010;16(13):3431-3441.
12. Kwon CH, Zhao D, Chen J, et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 2008;68(9): 3286-3294.
13. Huszthy PC, Daphu I, Niclou SP, et al. In vivo models of primary brain tumors: pitfalls and perspectives. Neuro Oncol. 2013;14(8): 979-993.
14. Gregorian C, Nakashima J, Le Belle J, et al. Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J Neurosci. 2009;29(6):1874-1886.
15. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett. 2007;251(1):1-16.
16. Guo Y, Yan K, Fang J, et al. Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res. 2013;32:41.
17. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359(6398):845-848.
18. Reardon DA,Wen PY, Desjardins A, et al. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008;8(4):541-553.
19. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA. 1998;95(26):15406-15411.
20. Furnari FB, Lin H, Huang HS, et al. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA. 1997;94(23):12479-12484.
21. McCall P, Witton CJ, Grimsley S, et al. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer. 2008;99(8):1296-1301.
22. Engelman JA. Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-562.
23. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
24. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res. 1997;3(9):1457-1466.
25. Latour LL, Svoboda K, Mitra PP, et al. Time-dependent diffusion of water in a biological model system. Proc Natl Acad Sci USA. 1994; 91(4):1229-1233.
26. Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012;108(3):491-498.
27. Lazovic J, Basu A, Lin HW, et al. Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke. 2005;36(10):2226-2231.
28. Hall DE, Moffat BA, Stojanovska J, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res. 2004;10(23):7852-7859.
29. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24): 2029-2036.
30. McConville P, Hambardzumyan D, Moody JB, et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res. 2007;13(10):2897-2904.
31. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-189.